720
Participants
Start Date
July 18, 2011
Primary Completion Date
February 4, 2014
Study Completion Date
April 30, 2014
Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus
0.5 mL, subcutaneous at age 9 to 12, 15 to 18 and 21 to 24 months.
DTaP IPV//Hib vaccine
0.5 mL, intramuscular
Placebo
0.5 mL, subcutaneous
Measles, mumps, and rubella vaccine
0.5 mL, subcutaneous
Pneumococcal vaccine
0.5 mL, intramuscular
Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus
0.5 mL, subcutaneous at age 9 to 12, 16 to 19 and 21 to 24 months
DTaP IPV//Hib vaccine
0.5 mL, intramuscular
Placebo
0.5 mL, subcutaneously
Measles, mumps, and rubella vaccine
0.5 mL, subcutaneous
Pneumococcal vaccine
0.5 mL, intramuscular
Acapulco de Juárez
Guadalajara
Monterrey
Mérida
Sanofi Pasteur, a Sanofi Company
INDUSTRY